Stifel Nicolaus upgraded BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) from Hold to Buy and announced a $67.00 price target. Stifel Nicolaus commented, "We believe anticipation around a YE13 GALNS launch provides a tangible floor in valuation near-term and are increasingly comfortable with PEG-PAL-associated value longer-term. While acknowledging visibility into BMN-701